Medivir AB Release: Positive Results From a Phase I Study With MIV-711 for the Treatment of Osteoarthritis and Other Bone Related Disorders

Published: Oct 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden – Medivir AB (OMX:MVIR) announced further results from the phase I clinical study on the investigational cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and other bone related disorders. The 7 day data was presented on October 6th at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Baltimore, USA.

Help employers find you! Check out all the jobs and post your resume.

Back to news